Krka d. d (0HLK) Stock Overview
A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
0HLK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €256.41 |
| 52 Week High | €256.41 |
| 52 Week Low | €229.54 |
| Beta | 0.41 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 270.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HLK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 1.0% |
| 1Y | n/a | 22.9% | 17.2% |
Return vs Industry: Insufficient data to determine how 0HLK performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0HLK performed against the UK Market.
Price Volatility
| 0HLK volatility | |
|---|---|
| 0HLK Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0HLK's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0HLK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 13,204 | Jože Colaric | www.krka.biz |
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabolism, and other therapeutic areas, as well as analgesics, vitamins, minerals, and vasoprotectives.
Krka, d. d. Fundamentals Summary
| 0HLK fundamental statistics | |
|---|---|
| Market cap | €8.14b |
| Earnings (TTM) | €372.00m |
| Revenue (TTM) | €2.08b |
Is 0HLK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HLK income statement (TTM) | |
|---|---|
| Revenue | €2.08b |
| Cost of Revenue | €864.10m |
| Gross Profit | €1.22b |
| Other Expenses | €848.59m |
| Earnings | €372.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 12.28 |
| Gross Margin | 58.55% |
| Net Profit Margin | 17.84% |
| Debt/Equity Ratio | 0% |
How did 0HLK perform over the long term?
See historical performance and comparisonDividends
Does 0HLK pay a reliable dividends?
See 0HLK dividend history and benchmarks| Krka d. d dividend dates | |
|---|---|
| Ex Dividend Date | Jul 21 2026 |
| Dividend Pay Date | Jul 23 2026 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 3 days |
Does 0HLK pay a reliable dividends?
See 0HLK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/18 15:46 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krka, d. d. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Mather | Barclays |
| Stephane Sumar | BNP Paribas |
| Jamie Clark | BofA Global Research |